Rznomics Joins Lilly Gateway Labs to Quicken RNA Therapeutic Candidate Discovery and Development
Through its entry into Lilly Gateway Labs, Rznomics officials say they plan to accelerate candidate discovery and development across its target gene database bank comprising over 200 disease targets. The post Rznomics Joins Lilly Gateway Labs to Quicken RNA Therapeutic Candidate Discovery and Development appeared first on GEN - Genetic Engineering and Biotechnology News .
Rznomics, a South Korean clinical-stage biopharmaceutical company specializing in RNA-based gene therapies, has joined forces with Lilly Gateway Labs in San Diego. Lilly Gateway Labs is part of Lilly Catalyze360, a network of Lilly entities that support biotech innovation through strategic capital, lab space, technology, and R&D capabilities.
Rznomics aims to accelerate candidate discovery and development across its extensive target gene database of over 200 disease targets. The collaboration will also focus on establishing a robust global clinical infrastructure, forging strategic partnerships worldwide, and recruiting top-tier R&D researchers in the United States. Seong-Wook Lee, CEO of Rznomics, expressed enthusiasm about the partnership, stating that it marks a significant step for the company's RNA platform and will facilitate the advancement of RNA therapeutic candidate discovery and commercialization through active collaboration with the global biotech ecosystem.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
